P728 Real world evidence for adalimumab biosimilar, MSB 11022, therapy in inflammatory bowel diseases: Adherence analysis
Cheung, S.(1)*;Truong, D.(1);
(1)Fresenius Kabi Canada, Medical Affairs, Toronto, Canada;
Background
Adherence to medication is crucial for maintaining remission in patients with inflammatory bowel diseases (IBD). Patient-support program (PSP) plays a significant role in education for patients on medication adherence. The objective of this project was to analyze the data collected by Fresenius Kabi PSP (KabiCare) in IBD patients population on their adherence to an adalimumab biosimilar, MSB 11022, in real world practice in Canada.
Methods
Patients with IBD enrolled in KabiCare and received at least one dose of adalimumab biosimilar, MSB 11022, were follow-up from Feb 2021 to Nov 2022 in Canada. Medication initiation date and stop date, disease types (Crohn’s disease [CD], and ulcerative colitis [UC]) and patient treatment (categorized by naïve to biologic, or switched from other biologics) were recorded in the database. The stop date was the date when KabiCare was informed that medication was discontinued. The patients continuing medication were censored at the maximal follow-up date of analysis, November 9, 2022. Log-rank tests were used for KM (Kaplan-Meier) plot comparison to examine if there were differences in medication adherence between CD and UC, and between naïve group vs. switch group by disease.
Results
The study sample consisted of 836 patients, 670 (80.0%) of whom had CD, and 266 (31.8%) were in naïve group. KabiCare followed patients for a median time of 291 days (interquartile range: 190-392 days; maximum: 622 days). At 600 days after starting the medicine, the adherence probability was similar for patients with CD and UC (At day-600: 83.4% vs. 82.2%, P=0.26); however, the adherence probability was higher in the switch group compared to naïve group (At day-600: 87.9% vs. 73.5%, P=0.0001). Among patients with CD, the adherence probability was higher with switch group compared to naïve group (At day-600: 88.8% vs. 71.7%, P=0.0001). Among patients with UC, the adherence probably was similar between switch group compared to naïve group (At day-600: 90.5% vs. 76.5%, P=0.11).
Conclusion
The adherence probability of adalimumab biosimilar, MSB 11022, was over 80% 600-day after initiating therapy, regardless of the type of IBD disease. Compared to patients in naïve group, patients in switch group were more likely to stay on adalimumab therapy. As far as we know, this is the first report of using adalimumab biosimilar, MSB 11022, in real world clinical practice of IBD.